Skip to main content
. 2015 Jan 13;125(10):1643–1652. doi: 10.1182/blood-2014-08-595751

Figure 3.

Figure 3

Elevated plasma adenosine induces erythrocyte SphK1 activity increase in vivo. (A) Schematic representation of mouse treatment strategy. (B) Plasma adenosine and (C) erythrocyte SphK1 activity in Ada+/−, Ada−/− with PEG-ADA treatment, Ada−/− without PEG-ADA treatment, and Ada−/− rescue. Values shown represent the mean ± SEM (n = 6 for each group). *P < .05 Ada−/− vs Ada−/−+ PEGADA;**P < .05 Ada−/− vs Ada−/− rescue.